// App-Quantinova.ai

3681 : Sustained Immune Competency and Long Term Molecular Remissions in FL Patients with FLIPI Risk Factors >1, Treated Front Line with R-CHOP Followed by Consolidative 90 Y-Radioimmunotherapy and Maintenance Rituximab

Researchers

Presenter

  • Nancy M Pennell

Principal Investigators

  • Mary-Anne Cussen

  • Kevin R Imrie

  • Eugenia Piliotis

  • Rena Buckstein

  • Zeina Ghorab

  • Ellen Anne Miles

  • Alden E. Chesney

  • Matthew Cheung

Medical Centers

  • Neonatology, Sunnybrook Health Sciences Centre, Toronto, Canada

  • Sunnybrook Health Sciences Centre and Odette Cancer Centre, Toronto, ON, Canada

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Neonatology, Sunnybrook Health Sciences Centre, Toronto, Canada

  • Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre and Odette Cancer Centre, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre and Odette Cancer Centre, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Follicular lymphoma

  • Congenital rubella

  • Measles

  • Sepsis

Biomarkers

  • Cluster of Differentiation 19

  • Cluster of Differentiation 2AP

  • Immunoglobulin G

Drug/Treatment

  • Rituximab

  • Ibritumomab tiuxetan; Zevalin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved